Back to Journals » Patient Preference and Adherence » Volume 19

The Concizumab Pen-Injector is Easy to Use and Preferred by Hemophilia Patients and Caregivers: A Usability Study Assessing Pen-Injector Handling and Preference [Corrigendum]

Authors Kahr Rasmussen N, Berg B, Christiansen ASL, Neergaard JS, Ter-Borch G, Hildebrand EA, Gonczi M, Sparre T

Received 19 March 2025

Accepted for publication 19 March 2025

Published 28 March 2025 Volume 2025:19 Pages 805—807

DOI https://doi.org/10.2147/PPA.S529186



Kahr Rasmussen N, Berg B, Christiansen ASL, et al. Patient Prefer Adherence. 2024;18:1713—1727.

Page 1719, Table 4, Range column, Total row under the Time to prepare and inject section, the text “0 min 29s–4 min 7s” should read “0 min 29s–4 min 3s”. The correct table is as follows.

Table 4 Measurements of training time, time to administer an injection, and the correct execution of the injection

Page 1719, Ease-of-Learning to Use and Ease-of-Use of the Concizumab Pen-Injector section, second line, the text “(n=78, 97%)” should read “(n=78, 98%)”.

Figure 3 on page 1720 is incorrect. The correct Figure 3 is as follows.

Figure 3 The ease of learning and ease of use of the pen-injector as assessed using the HDHPA questionnaire. (A) Responses from participants to HDHPA question 1 on factors associated with ease of handling and use of concizumab pen-injector. Participants were asked to select the response that most closely represented how they felt using the pen-injector. (B) Responses from participants to HDHPA question 2 on overall difficulty or ease of use of the concizumab pen-injector. Responses were assessed on a 5-point scale ranging from very difficult to very easy. Responses for very difficult and difficult were combined to represent negative results and the responses easy and very easy were combined to represent positive results. Data are presented as number of responses with percentages % (n).

Page 1722, Discussion section, eighth line, the text “(97%)” should read “(98%)”.

The authors apologize for these oversights.


Read the original article


Creative Commons License © 2025 The Author(s). This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, 4.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.